Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.